A controlled trial of topical Povidone-iodine to treat EKC

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015021518004N2

Enrollment

Registered

2015-06-01

Start date

2015-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidemic Keratoconjunctivitis. Superficial keratitis with conjunctivitis

Interventions

Intervention 1: Group 3 : Betamethasone drop 0.1%, Chloramphenicole drop, Artificial tear, All drops every 4 hour, 4 times daily for 9 days. Intervention 2: Group 1 : Povidone iodine 0.4% drop, Betam

Treatment - Drugs

Group 3 : Betamethasone drop 0.1%, Chloramphenicole drop, Artificial tear, All drops every 4 hour, 4 times daily for 9 days

Group 1 : Povidone iodine 0.4% drop, Betamethasone 0.1% drop, Artificial tear, Povidone iodine first 3 days every 4 hour,Second 3 days every 8 hour and third 3 days every 12 hour for 9 days overall

Group 2 : Povidone iodine 0.2% drop, Betamethasone 0.1% drop, Artificial tear, Povidone iodine first 3 days ever 4 hour,second 3 days every 8 hour and third 3 days every 12 hour for 9 days overally

Eligibility

Sex/Gender

All

Age

6 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Injection ? Purulent discharge ? Foreign body sensation ? Follicular conjunctival reaction ? Pthechia ;? Exclusion criteria: Pregnancy ? Steroid dependent glaucoma ? Herpes simplex keratitis history ? Symptoms for more than 3 days ? Less than 7 years old ? More than 50 years old ? And lack of follow-up visits? .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Injection. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Peri orbital edem. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Chemosis. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Bloody discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Foreign body sensation. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Tearing. Timepoint: 1 ,4, 7, 10 day. Method of measurement: Patient answer.;Feeling cure. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Sub epithelial opacity. Timepoint: 10th day. Method of measurement: Patient answer.	—

Measure

Time frame

Injection. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Peri orbital edem. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Chemosis. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Bloody discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Ophthalmologist visit.;Foreign body sensation. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Discharge. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Tearing. Timepoint: 1 ,4, 7, 10 day. Method of measurement: Patient answer.;Feeling cure. Timepoint: 1, 4, 7, 10 day. Method of measurement: Patient answer.;Sub epithelial opacity. Timepoint: 10th day. Method of measurement: Patient answer.

—

Secondary

Measure	Time frame
None. Timepoint: none. Method of measurement: none.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamreza Seyedpiran

Alzahra eye hospital, Zahedan

rezaseyyedpiran@gmail.com+98 54 3322 4991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026